The Supreme Court’s decision in Amgen Inc. v. Sanofi found that antibody claims defined by their binding and blocking function lacked enablement..The consensus seems to be that Amgen generally forecloses broad genus claims in the biotechnology field.
I’m a bit behind and therefore am not part of the slew of commentary that flowed from the Supreme Court’s decision in Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1248 (2023), addressing.
BiVictriX Therapeutics PLC appoints cancer research veteran as vice president of product development proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.